Australia-based Cancer Therapeutics has announced the validation and performance of CTx-294886 in combination with Avastin in a preclinical model of basal breast cancer, which showed additional benefits to those previously demonstrated by CTx-294945.
CTx-0294886 is a potent, small molecule inhibitor of focal adhesion kinase (FAK) and vascular endothelial growth factor receptor 3 (VEGFR3), which was compared with CTx-0294945, a potent selective FAK inhibitor.
Cancer Therapeutics CEO, Warwick Tong, said that the second candidate is even more potent at prolonging and strengthening the effects of Avastin compared to the first one.
"We are now starting to reap the benefits of our highly collaborative approach to drug discovery, working hand in hand with some of the top research institutes in Australia and our international partner, Cancer Research Technology UK," Tong added.
Both the small molecules in combination with Avastin inhibited angiogenesis and increased the duration of tumour response.
Additionally CTx-294886 in combination with Avastin provided a highly statistically significant increase in the median survival time compared to the Avastin only group.
The company has even developed a new high-throughput screening (HTS) platform for the identification of small molecule inhibitors of protein ubiquitination.
According to the company, the new ubiquitin HTS platform closely replicates cellular ubiquitination pathways, and provides a mechanism for HTS of multiple targets.
Cancer Therapeutics chief scientific officer, Ian Street, said the launch of the new ubiquitin HTS platform opens up the potential to collaborate with industry by screening chemical libraries to address multiple targets in the new area of cancer biology.
"We are ready to begin discussions with other companies who would like to work with us to include their targets of interest and screen their chemical libraries using this platform," Street added.